MUC1 Vaccine in Current and Former Smokers at High Risk for Lung Cancer

Phase 1, open-label, single-arm trial of MUC1 peptide-poly-ICLC vaccine in lung cancer, sponsored by National Cancer Institute. Primary endpoints: Number of Participants With Immunogenicity of the MUC1 Vaccine at 12 weeks and Count of Patients Experiencing 1 or More Grade 3+ Adverse Events at Least Possibly Related to Treatment at 24 weeks. Started Dec 2017; status: active, not recruiting.